Stocks股票 / Health Care / LGND
LGND US listed · USD美股 · 美元
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas.Ligand Pharmaceuticals 是一家美国生物制药公司,专注于收购和开发产生特许权使用费的资产。截至2024年,公司投资组合涵盖约90种跨治疗领域的药品特许权。
Company news公司新闻
The latest reporting最新报道
One story, with the reporting behind it.将同一事件汇总,保留各来源报道。
The latest call, in context把最新财报放回历史脉络
A synthesized event record across management commentary and recorded metrics. Read as context; verify exact wording in the transcript before relying.综合管理层表述与记录指标形成事件档案。仅供参考;使用前请在电话会原文中核对准确措辞。
Live company record实时公司记录
JavaScript loads the source-bounded event record here. Open Terminal if the live module does not start.JavaScript 会在此加载受来源约束的事件记录。如实时模块未启动,请打开终端。
Continue with full transcript history继续查看完整电话会历史 ↗Price chart价格图表
Technicals技术面
daily bars日线数据 · 2026-10-26Earnings财务业绩
next report下次财报 2026-11-05Estimates being raised — 2 analysts预期上调 — 2 位分析师
Beat in 3 of last 4 quarters近 4 季中 3 季超预期
EPS surprise vs consensus, last quarters每股收益相对预期的超预期幅度(近几个季度) · average平均 138.7%
Valuation估值
Expensive vs sector相对行业偏贵| Multiple指标 | LGND | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率(历史) | 48.23x | 31.50 | |
| P/B市净率 | 5.90x | 3.57 | |
| P/S市销率 | 22.39x | 3.19 | |
| Earnings yield盈利收益率 | 2.07% | 2.37 | |
| FCF yield自由现金流收益率 | 0.81% | 3.88 | |
| Shareholder yield股东收益率 | 0.25% | 1.83 | |
| EV/EBITDA企业价值/EBITDA | 77.93x | 19.32 | |
| P/FCF市值/自由现金流 | 122.72x | 23.56 |
Financials财务数据
fiscal years财年Leverage杠杆
Capital allocation资本配置
Debt coming due到期债务
FY2015 10-KThe 12-month bucket following fiscal period end 2015-12-31 is not reported. The years below are what the filing did report.文件未披露财年期末 2015-12-31 之后12个月区间的到期金额;下方为其确实披露的年度。
All maturity buckets are measured from fiscal period end 2015-12-31, not from today.所有到期区间均从财年期末 2015-12-31 起算,而非从今天起算。
Cash reported at 2025-12-31: $174927000.截至 2025-12-31 披露的现金:$174927000。 Operating cash flow exceeded or equaled equipment spending over 2025-01-01 to 2025-12-31; no cash burn to measure.在 2025-01-01 至 2025-12-31 期间,经营现金流不低于设备支出,无可衡量的现金消耗。
Capital-need coverage is partial; incomplete or incompatible filing inputs are not combined.资本需求覆盖信息不完整;不会合并不完整或不兼容的报告数据。
Any available cash-flow scenario is context only. Missing or incompatible inputs are not replaced with zero or a financing forecast.可用现金流情景仅供参考;缺失或不兼容的输入不以零值或融资预测替代。
Sources and cash-flow calculation来源与现金流计算
Figures are XBRL facts from one filing — no two years are mixed. Filing数据取自同一份文件中的 XBRL 事实,不跨文件拼接。文件
0000886163-16-000149, period ending报告期截至 2015-12-31, unit单位 USD.
Cache acquired缓存获取时间: 2026-09-27T08:39:27.065618+00:00.
1/6 buckets reported.个区间有披露。
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths— period_mismatchLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo— period_mismatchLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree— absentLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour— absentLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveLongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive— absent
Annual period年度区间 2025-01-01 — 2025-12-31 · USD · 10-K · 0000886163-26-000006 · Filed提交日期 2026-02-27.
Cache acquired缓存获取时间: 2026-09-27T08:39:27.065618+00:00 · Evaluated as of评估截至 2026-10-26.
- Reported operating cash flow已披露经营活动现金流: $49359000
- Reported equipment spending (capex outflow)已披露设备支出(资本开支流出): $452000
- Derived free cash flow (operating cash flow minus capex)计算所得自由现金流(经营现金流减资本开支): $48907000
Cash is the reported balance at period end. The runway scenario holds this annual cash-flow pace constant and excludes debt payments, restricted-cash adjustments and future financing.现金为期末已披露余额。现金跑道情景假设本年度现金流速度保持不变,不包括债务偿还、受限现金调整与未来融资。
Why is it moving为何波动
6 checks · nightly六项检查 · 每晚Ownership & smart money持仓与聪明钱
13FInsider activity:内部人动向: -$25.1M net (0 buyers, 8 sellers)-$25.1M 净值(0 买家,8 卖家)
Signal history信号历史
engine events引擎事件Company profile公司档案
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas.Ligand Pharmaceuticals 是一家美国生物制药公司,专注于收购和开发产生特许权使用费的资产。截至2024年,公司投资组合涵盖约90种跨治疗领域的药品特许权。
The whole US universe — S&P 1500 and Russell 2000 — read nightly.覆盖标普1500与罗素2000全部成分股 — 每晚更新解读。
Signals, options positioning, smart-money moves and factor DNA — the same engine that wrote this page covers 2,700+ US stocks.信号、期权持仓、聪明钱动向与因子基因 — 撰写本页的引擎覆盖2700多只美股。
Valuation vs sector估值对比行业
| Multiple指标 | This stock本股 | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率(静态) | 48.2× | 31.5× | 25% |
| Price / Book市净率 | 5.9× | 3.6× | 30% |
| Price / Sales市销率 | 22.4× | 3.2× | 3% |
| EV / EBITDAEV/EBITDA | 77.9× | 19.3× | 3% |
| Earnings yield盈利收益率 | 2.1% | 2.4% | 44% |
| Free-cash-flow yield自由现金流收益率 | 0.8% | 5.2% | 11% |
| Shareholder yield股东综合回报率 | 0.2% | 1.8% | 17% |
Relative strength相对强度
Price history价格历史
| Period周期 | This stock本股 | S&P 500标普500 |
|---|---|---|
| 1 Week近1周 | +2.7% | -0.4% |
| 1 Month近1月 | +1.7% | -1.0% |
| 3 Months近3月 | +1.0% | +3.1% |
| 6 Months近6月 | +31.2% | +7.0% |
| Year to date年初至今 | +59.7% | +12.1% |
| 1 Year近1年 | +63.8% | +14.4% |
| 3 Years近3年 | +484.9% | +86.0% |
Trading information交易信息
Multi-year record多年财务记录
| 20202020 | 20212021 | 20222022 | 20232023 | 20242024 | 20252025 | |
|---|---|---|---|---|---|---|
| Revenue营业收入 | $186M | $277M | $196M | $131M | $167M | $268M |
| EPS每股收益 | $-0.18 | $3.31 | $-1.98 | $2.94 | $-0.22 | $6.13 |
| Free cash flow自由现金流 | $50M | $70M | $120M | $46M | $95M | $49M |
| Gross margin毛利率 | — | — | — | — | — | — |
| Net margin净利率 | -1.6% | 20.6% | -17.0% | 39.7% | -2.4% | 46.4% |
| FCF margin自由现金流利润率 | 26.9% | 25.3% | 61.1% | 35.1% | 57.0% | 18.2% |
Latest fiscal year最近财年
Returns & growth回报与增长
Accounting quality checks会计质量检查
- Earnings quality: accruals trending up over 6 fiscal years — earnings increasingly not cash-backed盈利质量:应计利润在 6 个财年间走高——盈利的现金支撑减弱
- Working capital: inventory & receivables lean vs sales营运资本:存货与应收相对销售保持精简
- Capital discipline: share count +23.0% over 6 years (dilution)资本纪律:股本 6 年增加 23.0%(稀释)
- Balance sheet: Altman Z 8.04 — safe zone资产负债表:Altman Z 8.04——安全区
Indicator readings指标读数
Timeframe alignment多周期共振
Volatility regime波动状态
Surprise history超预期历史
| Quarter季度 | Reported实际 | Expected预期 | Surprise超预期 |
|---|---|---|---|
| Jun 2026 | $2.22 | $1.34 | +65.7% |
| Mar 2026 | $-0.67 | $0.98 | -168.4% |
| Dec 2025 | $2.12 | $0.63 | +236.5% |
| Sep 2025 | $5.68 | $1.09 | +421.1% |
Estimate revisions预期修正
Insiders & shorts内部人与空头
Recent fund flows近期基金流向
Month by month逐月统计
| Month月份 | Closed higher收涨占比 | Median move中位涨跌 | Years年数 |
|---|---|---|---|
| Jan1月 | 100% | +2.6% | 3 |
| Feb2月 | 100% | +5.3% | 3 |
| Mar3月 | 33% | -7.8% | 3 |
| Apr4月 | 67% | +5.2% | 3 |
| May5月 | 67% | +2.0% | 3 |
| Jun6月 | 67% | +11.0% | 3 |
| Jul7月 | 67% | +15.7% | 3 |
| Aug8月 | 33% | -0.9% | 3 |
| Sep9月 | 50% | +9.3% | 4 |
| Oct10月 | 50% | +6.0% | 4 |
| Nov11月 | 100% | +11.3% | 3 |
| Dec12月 | 33% | -6.9% | 3 |